- Home
- CIFR vs AVXL Comparison
CIFR vs AVXL Comparison
Compare CIFR & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- AVXL
- Stock Information
- Founded
- CIFR 2021
- AVXL 2004
- Country
- CIFR United States
- AVXL United States
- Employees
- CIFR N/A
- AVXL N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIFR Finance
- AVXL Health Care
- Exchange
- CIFR Nasdaq
- AVXL Nasdaq
- Market Cap
- CIFR 882.1M
- AVXL 710.3M
- IPO Year
- CIFR N/A
- AVXL N/A
- Fundamental
- Price
- CIFR $3.12
- AVXL $7.53
- Analyst Decision
- CIFR Strong Buy
- AVXL Strong Buy
- Analyst Count
- CIFR 10
- AVXL 2
- Target Price
- CIFR $8.03
- AVXL $44.00
- AVG Volume (30 Days)
- CIFR 20.8M
- AVXL 948.5K
- Earning Date
- CIFR 05-06-2025
- AVXL 05-13-2025
- Dividend Yield
- CIFR N/A
- AVXL N/A
- EPS Growth
- CIFR N/A
- AVXL N/A
- EPS
- CIFR N/A
- AVXL N/A
- Revenue
- CIFR $152,092,000.00
- AVXL N/A
- Revenue This Year
- CIFR $90.57
- AVXL N/A
- Revenue Next Year
- CIFR $78.51
- AVXL N/A
- P/E Ratio
- CIFR N/A
- AVXL N/A
- Revenue Growth
- CIFR N/A
- AVXL N/A
- 52 Week Low
- CIFR $1.86
- AVXL $3.51
- 52 Week High
- CIFR $7.99
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- CIFR 46.63
- AVXL 38.43
- Support Level
- CIFR $3.34
- AVXL $7.26
- Resistance Level
- CIFR $3.65
- AVXL $7.80
- Average True Range (ATR)
- CIFR 0.27
- AVXL 0.45
- MACD
- CIFR -0.04
- AVXL -0.06
- Stochastic Oscillator
- CIFR 11.24
- AVXL 24.34
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.